American Medical Association: Why this Black doctor volunteered for coronavirus vaccine trial
Dr. Louito Edje, UC associate dean and UC Health physician, wanted to support her patients
The American Medical Association interviewed Louito Edje, MD, associate dean of graduate medical education and designated institutional official at the University of Cincinnati College of Medicine, about the race to develop a COVID-19 vaccine and Edje’s decision to take part in a clinical trial. Too few of the people participating are Black, but it’s not surprising given the long-running difficulty that clinical trials have encountered in recruiting Black research subjects given high levels of historical mistrust.
Louito Edje, MD
Edge, a professor in the Department Medical Education and the Department of Family and Community Medicine, is also a UC Health physician. She joined the Phase 3 clinical trial for a SARS-CoV-2 vaccine. UC is one of approximately 90 sites in the U.S. to host a trial for the mRNA-1273 vaccine developed by National Institute of Allergy and Infectious Diseases scientists and collaborators at biotechnology company Moderna.
Her decision to enroll in the federally funded study was an easy one. Edje dedicates many of her working hours overseeing more than 700 resident and fellow physicians who train at UC Health. During the COVID-19 pandemic, that means ensuring learners are safe as they provide frontline care.
Read Dr. Edje’s interview with the American Medical Association online.
Related Stories
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.
UC Board of Trustees approves $12 million for building design phase for new welcome gateway
March 13, 2026
The UC Board of Trustees approved $12 million at its Feb. 24 meeting for the design phase of a new Welcome Gateway Building for Uptown campus.